Education
About Us
Working with TipRanks
Follow Us
Calidi Biotherapeutics (CLDI)
:CLDI
CLDI Stock Chart & Stats
$1.46
-$0.04(-2.72%)
At close: 4:00 PM EST
$1.46
-$0.04(-2.72%)
Day’s Range― - ―
52-Week Range$1.10 - $22.68
Previous CloseN/A
Volume567.49K
Average Volume (3M)164.15K
Market Cap
$7.35M
Enterprise Value$6.88M
Total Cash (Recent Filing)$10.38M
Total Debt (Recent Filing)$3.11M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Mar 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding4,899,210
10 Day Avg. Volume193,319
30 Day Avg. Volume164,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.47
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.25
Enterprise Value/Ebitda-0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataEarly clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.
Regulatory ApprovalThe FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).
Bears Say
Financial StabilityGiven the company's financial situation, even after the offering, there appears to be meaningful risk to the company continuing as a going concern.
Calidi Biotherapeutics News
CLDI FAQ
What was Calidi Biotherapeutics’s price range in the past 12 months?
Calidi Biotherapeutics lowest stock price was $1.10 and its highest was $22.68 in the past 12 months.
What is Calidi Biotherapeutics’s market cap?
Calidi Biotherapeutics’s market cap is $7.35M.
When is Calidi Biotherapeutics’s upcoming earnings report date?
Calidi Biotherapeutics’s upcoming earnings report date is Mar 13, 2026 which is in 88 days.
How were Calidi Biotherapeutics’s earnings last quarter?
Calidi Biotherapeutics released its earnings results on Nov 13, 2025. The company reported -$2.21 earnings per share for the quarter, missing the consensus estimate of -$1.68 by -$0.53.
Is Calidi Biotherapeutics overvalued?
According to Wall Street analysts Calidi Biotherapeutics’s price is currently Overvalued.
Does Calidi Biotherapeutics pay dividends?
Calidi Biotherapeutics does not currently pay dividends.
What is Calidi Biotherapeutics’s EPS estimate?
Calidi Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Calidi Biotherapeutics have?
Calidi Biotherapeutics has 4,899,210 shares outstanding.
What happened to Calidi Biotherapeutics’s price movement after its last earnings report?
Calidi Biotherapeutics reported an EPS of -$2.21 in its last earnings report, missing expectations of -$1.68. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Calidi Biotherapeutics?
Currently, no hedge funds are holding shares in CLDI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Calidi Biotherapeutics
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
Entero Therapeutics
―
Adial Pharmaceuticals
―
Cardio Diagnostics Holdings
―
Ownership Overview
7.23% Insiders
0.48% Mutual Funds
1.19% Other Institutional Investors
90.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---